文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

成功脱离肾脏替代治疗的预测因素:DOORS研究

Predictive factors of successful renal replacement therapy weaning : Deciding On patients Orientations after Renal replacement therapy Stopping (The DOORS study).
PubMed 文献 · Intensive Care Med · 2026-03-17
一句话结论UNDERSCORE床旁工具可估算临床医生启动停用肾脏替代治疗后持续脱离的概率,推导队列AUC 0.86,外部验证AUC 0.73。

该研究为AKIKI与AKIKI2两项多中心随机试验的事后分析,纳入KDIGO 3期AKI且采用保守启动策略的ICU患者,定义脱离尝试为停用肾脏替代治疗≥3天,主要结局为7天内无需重启肾脏替代治疗。554例接受肾脏替代治疗的患者中180例进行了脱离尝试,101例(56%)成功脱离。构建的UNDERSCORE包含6个预测因素,推导队列AUC 0.86(95%CI 0.80-0.91),在瑞士外部队列(n=415,338例即81%成功脱离)中AUC 0.73(95%CI 0.66-0.80)。该工具可在床旁估算临床医生启动停用后持续脱离肾脏替代治疗的概率。

要点

  • 554例接受肾脏替代治疗的KDIGO 3期AKI患者中,180例进行了脱离尝试(停用≥3天),101例(56%)在7天内无需重启肾脏替代治疗。
  • UNDERSCORE包含6个预测因素:脱离尝试前肾脏替代治疗时长、入院时脓毒性休克、基线血清肌酐,以及脱离尝试后3个临床变量(使用血管升压药、有创机械通气、尿量)。
  • 推导队列中UNDERSCORE区分度AUC 0.86(95%CI 0.80-0.91)。
  • 外部瑞士ICU队列(n=415)中338例(81%)成功脱离,UNDERSCORE区分度AUC 0.73(95%CI 0.66-0.80)。
  • UNDERSCORE为床旁工具,用于估算临床医生启动停用肾脏替代治疗后持续脱离的概率,支持停用后管理决策。

适用人群与场景

  • ICU内KDIGO 3期急性肾损伤且采用保守启动策略管理、并进行了肾脏替代治疗脱离尝试的患者。
  • 脱离尝试定义为停用肾脏替代治疗≥3天。

诊断标准与关键阈值

  • 急性肾损伤诊断分期采用KDIGO 3期标准。
  • 肾脏替代治疗脱离尝试定义为停用肾脏替代治疗≥3天。
  • 主要结局成功脱离定义为停用后7天内无需重启肾脏替代治疗。

研究设计与关键结果

  • 研究类型为AKIKI与AKIKI2两项多中心随机试验的事后分析,纳入ICU内KDIGO 3期急性肾损伤且采用保守启动策略管理的患者。
  • 554例接受肾脏替代治疗的患者中180例进行了脱离尝试,101例(56%)成功脱离。
  • 通过多变量逻辑回归保留6个独立预测因素构建UNDERSCORE:脱离尝试前肾脏替代治疗时长、入院时脓毒性休克、基线血清肌酐,以及脱离尝试后使用血管升压药、有创机械通气、尿量。
  • 推导队列中UNDERSCORE区分度AUC 0.86(95%CI 0.80-0.91)。
  • 外部瑞士ICU队列(n=415)中338例(81%)成功脱离,UNDERSCORE区分度AUC 0.73(95%CI 0.66-0.80)。

证据类型、等级与局限

  • 证据类型:两项多中心随机试验(AKIKI与AKIKI2)的事后分析,并在独立瑞士ICU队列中进行外部验证。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于KDIGO 3期急性肾损伤且采用保守启动策略、已停用肾脏替代治疗≥3天的ICU患者,UNDERSCORE可在床旁估算7天内无需重启肾脏替代治疗的概率。
  • UNDERSCORE的预测因素包括脱离尝试前肾脏替代治疗时长、入院时脓毒性休克、基线血清肌酐,以及脱离尝试后使用血管升压药、有创机械通气、尿量。
  • UNDERSCORE在推导队列中区分度AUC 0.86(95%CI 0.80-0.91),在外部瑞士ICU队列中区分度AUC 0.73(95%CI 0.66-0.80),用于支持停用后管理决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Renal replacement therapy (RRT) is a life-saving intervention in severe acute kidney injury (AKI). After a clinician-initiated discontinuation, the likelihood of sustained liberation remains uncertain. We aimed to identify predictors of successful RRT weaning and to develop a pragmatic bedside tool (the UNDERSCORE) to support post-discontinuation management.

METHODS: This post-hoc analysis of two multicenter randomized trials (AKIKI and AKIKI2) included ICU patients with KDIGO stage 3 AKI managed with a conservative initiation approach. Patients were eligible if they underwent an RRT weaning attempt, defined as discontinuation for ≥ 3 consecutive days. The primary outcome was successful weaning, i.e., no RRT resumption within seven days. Independent predictors were identified using multivariable logistic regression, and the resulting model (UNDERSCORE) was externally validated in an independent Swiss ICU cohort.

RESULTS: Among 554 patients who received RRT, 180 underwent a weaning attempt and 101 (56%) were successfully weaned. Six predictors were retained to construct the UNDERSCORE: RRT duration before the attempt, septic shock on admission, baseline serum creatinine, and three clinical variables assessed after the weaning attempt (use of vasopressors, invasive mechanical ventilation, and urine output). The score showed strong discrimination in the derivation cohort (AUC 0.86, 95% CI 0.80-0.91). In the external Swiss cohort (n = 415), 338 patients (81%) were successfully weaned, with fair performance across a broader case mix (AUC 0.73, 95% CI 0.66-0.80).

CONCLUSION: The UNDERSCORE, derived from a homogeneous conservative RRT initiation cohort and validated in a diverse ICU population, provides a bedside tool to estimate the probability of sustained RRT discontinuation after an initial clinician-initiated stop.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Chaïbi K, Akrour Y, Louis G, et al. Predictive factors of successful renal replacement therapy weaning : Deciding On patients Orientations after Renal replacement therapy Stopping (The DOORS study). Intensive Care Med. 2026. PMID: 41843064. doi:10.1007/s00134-026-08357-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。